金(i)-NHC配合物抗癌剂的合理设计:诱导肺腺癌的坏死和旁凋亡。

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2025-06-19 DOI:10.1039/D5MD00290G
Sayari Dewan, Himanshu Sonker, Kajal Chaudhary and Ritika Gautam Singh
{"title":"金(i)-NHC配合物抗癌剂的合理设计:诱导肺腺癌的坏死和旁凋亡。","authors":"Sayari Dewan, Himanshu Sonker, Kajal Chaudhary and Ritika Gautam Singh","doi":"10.1039/D5MD00290G","DOIUrl":null,"url":null,"abstract":"<p >Gold(<small>I</small>)-NHC complexes bearing sterically demanding ligands remain largely underexplored as anticancer agents. In this study, we rationally designed and synthesized a series of gold(<small>I</small>)-NHC complexes derived from cytotoxic 1,10-phenanthroline-based NHC ligands. Comprehensive structural characterization was performed using <small><sup>1</sup></small>H and <small><sup>13</sup></small>C NMR spectroscopy, ESI-MS, IR spectroscopy, and single-crystal X-ray diffraction. Among the synthesized complexes <strong>AuL1–AuL7</strong>, <strong>AuL4</strong> emerged as the most active compound, exhibited potent anticancer activity, triggering mitochondrial membrane depolarization and inducing necroptosis and paraptosis in human lung adenocarcinoma (A549) cells—a mechanism distinct from conventional apoptosis-inducing gold complexes. Notably, <strong>AuL4</strong> effectively suppressed both metastasis and clonal expansion of malignant cells, reinforcing the therapeutic potential of gold-based chemotherapeutics. These findings establish <strong>AuL4</strong> and its analogues as promising candidates for the development of next-generation gold(<small>I</small>)-NHC anticancer agents, particularly for treating apoptosis-resistant lung cancers.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 9","pages":" 4208-4219"},"PeriodicalIF":3.5970,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rational design of gold(i)-NHC complexes as anticancer agents: induction of necroptosis and paraptosis in lung adenocarcinoma†\",\"authors\":\"Sayari Dewan, Himanshu Sonker, Kajal Chaudhary and Ritika Gautam Singh\",\"doi\":\"10.1039/D5MD00290G\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Gold(<small>I</small>)-NHC complexes bearing sterically demanding ligands remain largely underexplored as anticancer agents. In this study, we rationally designed and synthesized a series of gold(<small>I</small>)-NHC complexes derived from cytotoxic 1,10-phenanthroline-based NHC ligands. Comprehensive structural characterization was performed using <small><sup>1</sup></small>H and <small><sup>13</sup></small>C NMR spectroscopy, ESI-MS, IR spectroscopy, and single-crystal X-ray diffraction. Among the synthesized complexes <strong>AuL1–AuL7</strong>, <strong>AuL4</strong> emerged as the most active compound, exhibited potent anticancer activity, triggering mitochondrial membrane depolarization and inducing necroptosis and paraptosis in human lung adenocarcinoma (A549) cells—a mechanism distinct from conventional apoptosis-inducing gold complexes. Notably, <strong>AuL4</strong> effectively suppressed both metastasis and clonal expansion of malignant cells, reinforcing the therapeutic potential of gold-based chemotherapeutics. These findings establish <strong>AuL4</strong> and its analogues as promising candidates for the development of next-generation gold(<small>I</small>)-NHC anticancer agents, particularly for treating apoptosis-resistant lung cancers.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 9\",\"pages\":\" 4208-4219\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2025-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00290g\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00290g","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

携带空间要求配体的金(i)-NHC配合物作为抗癌剂在很大程度上尚未得到充分的开发。在本研究中,我们合理设计并合成了一系列由细胞毒性1,10-菲罗啉类NHC配体衍生的金(i)-NHC配合物。采用1H和13C NMR、ESI-MS、IR、单晶x射线衍射等方法进行了全面的结构表征。在合成的配合物AuL1-AuL7中,AuL4是活性最强的化合物,表现出强大的抗癌活性,可触发线粒体膜去极化,诱导人肺腺癌(A549)细胞的坏死和旁凋亡,这一机制与传统的诱导凋亡的金配合物不同。值得注意的是,AuL4有效地抑制了恶性细胞的转移和克隆扩增,增强了金基化疗药物的治疗潜力。这些发现表明,AuL4及其类似物是开发下一代金(i)-NHC抗癌药物的有希望的候选者,特别是用于治疗凋亡抵抗性肺癌。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Rational design of gold(i)-NHC complexes as anticancer agents: induction of necroptosis and paraptosis in lung adenocarcinoma†

Rational design of gold(i)-NHC complexes as anticancer agents: induction of necroptosis and paraptosis in lung adenocarcinoma†

Gold(I)-NHC complexes bearing sterically demanding ligands remain largely underexplored as anticancer agents. In this study, we rationally designed and synthesized a series of gold(I)-NHC complexes derived from cytotoxic 1,10-phenanthroline-based NHC ligands. Comprehensive structural characterization was performed using 1H and 13C NMR spectroscopy, ESI-MS, IR spectroscopy, and single-crystal X-ray diffraction. Among the synthesized complexes AuL1–AuL7, AuL4 emerged as the most active compound, exhibited potent anticancer activity, triggering mitochondrial membrane depolarization and inducing necroptosis and paraptosis in human lung adenocarcinoma (A549) cells—a mechanism distinct from conventional apoptosis-inducing gold complexes. Notably, AuL4 effectively suppressed both metastasis and clonal expansion of malignant cells, reinforcing the therapeutic potential of gold-based chemotherapeutics. These findings establish AuL4 and its analogues as promising candidates for the development of next-generation gold(I)-NHC anticancer agents, particularly for treating apoptosis-resistant lung cancers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信